BCL2 and cancer: This has important implications for approaches which use TRAIL and TRAIL receptor-based therapies to engage the extrinsic pathway as cancer cells which require tBID activation of intrinsic pathway may be rendered resistant by changes in the levels of BCL-2 proteins (such as overexpression of BCL-2) upon death receptor activation.